Drug
Florbetaben f-18 clinical trials
Also written Neuraceq and Florbetaben.
- studies test it
- 15
- open now
- 1
- in phase 3
- 2
- first study started
- 2008
Keep track of what changes. Save the florbetaben f-18 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
15 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 2
- Phase 4
- 1
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 7
Life Molecular Imaging SA (3) · Lantheus Germany GmbH (2) · Lantheus Biosciences Ltd. (2) · New York State Psychiatric Institute (1) · Sinotau Pharmaceutical Group (1) · Stanford University (1) · Ulsan University Hospital (1) · Molecular NeuroImaging (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses florbetaben f-18 is read from its arms, and is right about nine times in ten.
Testing it · 15
- Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine ImagingNot yet recruitingNot applicableUniversity of ZurichNCT07624760Written as ¹⁸F-florbetaben
- Test-retest Study With [18F]FBB in Cardiac AmyloidosisCompletedPhase 1Lantheus Germany GmbHNCT06790394Written as Florbetaben F18
- Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With ADCompletedPhase 4Lantheus Biosciences Ltd.NCT02681172Written as Neuraceq (florbetaben 18F)
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedPhase 3Lantheus Germany GmbHNCT05184088Written as [18F]florbetaben
- Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography StudyWithdrawnPhase 2Fundacion Clinic per a la Recerca BiomédicaNCT03057938Written as 18F-Florbetaben (FBB)
- Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CTTerminatedEarly Phase 1University of PennsylvaniaNCT04105634Written as Florbetaben
- Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172CompletedNot applicableNew York State Psychiatric InstituteNCT01222351Written as BAY 94-9172 (Florbetaben)
- A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationCompletedNot applicableSinotau Pharmaceutical GroupNCT05527288Written as Drug: [18F]florbetaben
- PET/MRI Evaluation of Cardiac AmyloidCompletedEarly Phase 1Stanford UniversityNCT03119558Written as 18F-Florbetaben (Neuraceq®) PET/MRI
- Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission TomographyCompletedNot applicableUlsan University HospitalNCT03779815Written as [18F]Florbetaben
- Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesCompletedEarly Phase 1Molecular NeuroImagingNCT02531360Written as [18F]MNI-815 (MNI-815)
- Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to HistopathologyCompletedPhase 3Life Molecular Imaging SANCT01020838Written as Florbetaben (BAY94-9172)
- Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy VolunteersCompletedPhase 2Life Molecular Imaging SANCT00750282Written as Florbetaben (BAY94-9172)
- Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) PatientsCompletedPhase 1Lantheus Biosciences Ltd.NCT01138111Written as Florbetaben (BAY94-9172)
- Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.CompletedPhase 2Life Molecular Imaging SANCT00928304Written as Florbetaben (BAY94-9172)
Given in every arm · 1 — florbetaben f-18 is usual care beside what is tested
Codes
What other systems call florbetaben f-18 · ClinicalTrials.gg INT005250
- MeSH (NLM) C5277564-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbeneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TLA7312TOIFLORBETABEN F-18Confirmed FDA, NLM, Wikidata
- RxNorm 1492940Confirmed FDA, Wikidata
- Wikidata Q17014149florbetaben f-18Confirmed FDA, NLM, Wikidata
- DrugBank DB09148One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527756 | 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TLA7312TOI | FLORBETABEN F-18 | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1492940 | — | Confirmed FDA, Wikidata |
| Wikidata | Q17014149 | florbetaben f-18 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB09148 | — | One source Wikidata |
Also registered as florbetaben (UNII BMO5G62HGB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.